![Seng Chin Mah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Seng Chin Mah
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BioVersys AG
![]() BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | Vorsitzender | - | - |
Karriereverlauf von Seng Chin Mah
Ehemalige bekannte Positionen von Seng Chin Mah
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Canyon Pharmaceuticals, Inc.
![]() Canyon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Canyon Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. Its products include Revasc and Iprivask. The firm produces products to treat various immunity diseases. The company is headquartered in Hunt Valley, MD. | Vorstandsvorsitzender | - | - |
Vorsitzender | 03.08.2009 | - |
Statistik
International
Vereinigte Staaten | 2 |
Schweiz | 2 |
Operativ
Chairman | 2 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Canyon Pharmaceuticals, Inc.
![]() Canyon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Canyon Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. Its products include Revasc and Iprivask. The firm produces products to treat various immunity diseases. The company is headquartered in Hunt Valley, MD. | Health Technology |
BioVersys AG
![]() BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
- Börse
- Insiders
- Seng Chin Mah
- Erfahrung